Status:
COMPLETED
Retrospective Study on the Safety and Therapeutic/Improvement Effects of Intravenous Administration of SHED-CM for ALS (SHED-CAH2023)
Lead Sponsor:
Hitonowa Medical
Conditions:
Amyotrophic Lateral Sclerosis
Eligibility:
All Genders
38-81 years
Brief Summary
In this study, we will retrospectively evaluate the safety and efficacy of administering SHED-CM for the treatment of ALS.
Detailed Description
Amyotrophic Lateral Sclerosis (ALS) is a progressive and irreversible neurodegenerative disease with limited treatment options. Advances in regenerative medicine have opened new avenues for therapeuti...
Eligibility Criteria
Inclusion
- patients who visited our clinic between January 1, 2022 and November 30, 2023 and have been diagnosed with ALS
- male and female patients aged between 16 and 90 years old
- ALSFRS-R score of 12 or more at the time of initial visit
Exclusion
- Patients who have a tracheostomy at the time of visit.
- Patients who have expressed their refusal to participate in this study.
Key Trial Info
Start Date :
December 25 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2024
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06608719
Start Date
December 25 2023
End Date
July 1 2024
Last Update
September 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hitonowa Medical
Chiyoda City, Tokyo, Japan, 102-0085